Recommendation: Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Potential Upside* |
|---|---|---|---|---|---|---|---|
| 27 Mar, 25 | WVE | Buy | USD 10.02 | USD 10.52 | USD 10.92 | 1 day | 9.0% |
*Potential Upside (%) indicates the expected percentage increase from the Entry Price to the Target 2 Price.
Data Powered by EOD Historical Data (“EODHD”).
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Cash Position: Wave’s cash and cash equivalents grew by over 50%, reaching $302.1 million, extending its operational runway into 2027
Revenue Growth: Q4 2024 revenue increased by 187% year-over-year, rising from $29.1 million to $83.7 million
Annual Net Loss: The company’s full-year net loss widened from $57.5 million in 2023 to $97.0 million in 2024, reflecting increased spending on clinical trials
Rising R&D Expenses: Full-year R&D costs increased by approximately 23% from $130.0 million in 2023 to $159.7 million in 2024
Wave Life Sciences’ financial health remains reliant on successful clinical trial outcomes and regulatory approvals, making it vulnerable to potential setbacks in its development pipeline.
| Entry Price | Support* | Target 1 | Target 2 |
|---|---|---|---|
| 10.02 | 8.88 | 10.52 | 10.92 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
Clinical Progress Across Multiple RNA Medicine Programs
Wave Life Sciences (Nasdaq: WVE) has made significant strides in its clinical development programs, particularly with WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency (AATD). The company has completed enrollment in the first single-dose cohort of its INLIGHT trial for WVE-007, with clinical data expected in the second half of 2025. Additionally, multi-dosing has commenced in the 200 mg cohort of the RestorAATion-2 study for WVE-006, with a second single-dose cohort initiated at 400 mg. These advancements underscore Wave’s commitment to RNA-based therapeutics targeting high-impact diseases.
Exon Skipping and Antisense Silencing Programs Show Steady Advancement
In the Duchenne muscular dystrophy (DMD) space, Wave remains on track to deliver 48-week clinical data from its FORWARD-53 study evaluating WVE-N531. Results are expected in the first quarter of 2025, alongside regulatory feedback on a potential pathway for accelerated approval. Meanwhile, the company is preparing an Investigational New Drug (IND) submission for its potentially registrational Phase 2/3 study of WVE-003 for Huntington’s disease (HD) in the second half of 2025. The study will utilize caudate atrophy as a primary endpoint, following positive preliminary feedback from the FDA regarding Wave’s proposed biomarker-driven approach.
Robust Financial Position and Revenue Growth
As of December 31, 2024, Wave reported cash and cash equivalents of $302.1 million, a substantial increase from $200.4 million at the end of 2023. This financial position extends the company’s projected operational runway into 2027. Revenue for Q4 2024 surged to $83.7 million, compared to $29.1 million in Q4 2023, while full-year revenue stood at $108.3 million. These gains were largely driven by milestone payments and research funding from Wave’s collaboration with GSK.
Increased Research Investment and Rising Operational Costs
Wave’s research and development (R&D) expenses rose to $44.6 million in Q4 2024, up from $34.1 million in the same period the previous year, with full-year R&D costs reaching $159.7 million. This increase reflects the company’s expansion of its clinical programs and pipeline investments. Additionally, general and administrative expenses grew to $16.1 million in Q4 2024 from $13.7 million in Q4 2023, contributing to a full-year total of $59.0 million.
Positive Net Income in Q4 2024 Amid Annual Net Loss
Wave posted a net income of $29.3 million for Q4 2024, marking a sharp turnaround from a net loss of $16.3 million in Q4 2023. However, the company reported a full-year net loss of $97.0 million for 2024, widening from $57.5 million in 2023. This highlights the financial challenges of clinical-stage biotech companies, despite revenue growth in certain quarters.
Continued Pipeline Expansion and Strategic Focus
Beyond its current clinical trials, Wave is advancing its RNA editing programs, including investigational therapies for liver disease and familial hypercholesterolemia. The company plans to initiate clinical development for its PNPLA3, LDLR, and APOB-targeting programs in 2026. By leveraging its proprietary RNA chemistry and GalNAc conjugation technology, Wave aims to further establish its leadership in RNA-based therapeutics.
Considering recent key business, financial updates, current trading levels, and key business risks, a ‘Buy’ recommendation has been given on Wave Life Sciences Ltd (NASDAQ: WVE) at the closing market price of USD 10.02, as on March 26, 2025.
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences Ltd |
-0.01 0.12% | 8.07 | - | - | 6.26 | 17.90 | 4.77 | -9.2025 |
| NVO Novo Nordisk A/S |
-0.8143 1.17% | 68.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.0025 0.0036% | 68.96 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.03 0.0062% | 484.85 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-7.26 1.14% | 626.97 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Data Powered by EOD Historical Data (“EODHD”).
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is March 26,2025. The reference data in this report has been partly sourced from REFINITIV.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2023 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
